Group 1 - The core index of the Hong Kong Stock Connect Innovative Drug ETF (520880) has been timely adjusted, leading to significant price increases in several newly added constituent stocks [1][3] - The stock of Yaojie Ankang-B surged over 80% on September 12, reaching a new high of over 200 HKD, with its price doubling in three days [1][2] - The ETF now exclusively tracks innovative drug development companies, reflecting the trends in the innovative drug industry [3][4] Group 2 - Yaojie Ankang-B's core product, Tinengotinib, received approval for a Phase II clinical trial for breast cancer on September 10 [2][3] - The ETF has seen increased capital inflow since its adjustment to focus solely on innovative drug companies, with significant net subscriptions occurring [4][6] - China's share of global new drug research has surpassed 20%, positioning it as the second-largest in the world, with several domestic innovative drugs receiving approval [6]
港股通创新药新进大牛股！盘中疯涨超80%，股价翻倍仅用3天！100%创新药研发标的“520880”大幅溢价
Xin Lang Ji Jin·2025-09-12 05:40